ClinicalTrials.gg
CompletedNCT02402530Updated May 9, 2018

Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I

A Phase 2/3 interventional study of Placebo and Neridronic acid 62.5 mg in Complex Regional Pain Syndrome, Type I, sponsored by Grünenthal GmbH. Completed at 59 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-09.

Sponsored by Grünenthal GmbH · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2016, 10 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2018.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Reflex Sympathetic Dystrophy with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Reflex Sympathetic Dystrophy · United States.

Enrollment
Largest of 12
459 · median 113
Started
2015
with 1 other
Phase 2/3
2 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
3 of 15
Grünenthal GmbH

Among the 15 studies in Reflex Sympathetic Dystrophy with a site in United States, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2015, is one of 2 in phase 2/3, and was the 9th registered.

Reflex Sympathetic Dystrophy

43 studies on the registry are indexed under Reflex Sympathetic Dystrophy; 4 are open to participants now.

Browse Reflex Sympathetic Dystrophy studies →

Open to participants now

2 of the 15 studies in Reflex Sympathetic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Reflex Sympathetic Dystrophy studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Reflex Sympathetic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I).

The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and an extended follow-up period with visits at Month 6, Month 9, and Month 12. The extended follow-up period will be terminated for all participants after the last participant enrolled completes their Month 6 visit (Visit 9). The double-blind will be maintained throughout the 12-week trial period and extended follow-up period.

03

Conditions studied

  • Complex Regional Pain Syndrome, Type I

Keywords

  • Neridronic Acid
  • Neridronate
  • CRPS
  • RSD
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed.
  • Male or female participant between 18 years and 80 years of age.
  • A diagnosis of complex regional pain syndrome type I according to the clinical diagnostic criteria using the International Association for the Study of Pain clinical diagnostic criteria (Budapest criteria).
  • Baseline Pain Intensity Score of 4 or greater using an 11-point Numerical Rating Scale referring to the CRPS-affected limb.
  • In stable treatment and follow-up therapy for CRPS type I for at least 1 month.
  • Participant has undergone a recent regular dental examination.
  • Women of must have a negative urine ß-HCG pregnancy test at enrollment.
  • Women of child-bearing potential must practice protocol defined acceptable methods of during the trial.
  • Participants must be able to communicate meaningfully, be able to differentiate with regard to location and intensity of the pain, and be able to answer the questions in the questionnaires used in this trial.
  • Compliance with the use of electronic diary assessed prior to allocation to treatment.

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of complex regional pain syndrome type II.
  • Documented history or diagnosis of peripheral neuropathy, including diabetic peripheral neuropathy or other metabolic or toxic neuropathy, or any other chronic pain condition that would significantly affect a participant's ability to report CRPS-related pain.
  • Body weight less than 40 kg.
  • Evidence of renal impairment or a history of chronic kidney disease.
  • Serum calcium or magnesium outside of the central laboratory's reference range; history of hypocalcemia; any metabolic disorder anticipated to increase risk for hypocalcemia.
  • Vitamin D deficiency. Participants with vitamin D deficiency prior to enrollment may be enrolled with appropriate supplementation during the enrollment period.
  • interval greater than 470 milliseconds; treatment with medications within the last 30 days prior to allocation to IMP that have potential to prolong the QT interval or anticipated need for such medications during the course of the trial.
  • Any prior use of a bisphosphonate for treatment of CRPS, any prior administration of intravenous bisphosphonate, administration of oral bisphosphonate within the previous year, anticipated requirement for treatment with oral or intravenous bisphosphonate for another condition such as osteoporosis during the trial, or administration of denosumab (Prolia) or other bone turnover suppressing drugs within the past 6 months.
  • History of any allergic or reaction to neridronic acid or other bisphosphonate, or to vitamin D or calcium supplements.
  • Recent tooth extraction, unhealed or infected extraction site, or significant dental/periodontal disease that may pre-dispose to need for tooth extraction or other invasive dental procedures during the trial.
  • Evidence of denture-related gum trauma or improperly fitting dentures causing injury.
  • Prior radiation therapy of the head or neck (within 1 year of enrollment).
  • Recent treatment with high doses of systemic or anticipated need for concomitant high-dose steroid treatment during the trial.
  • History of within 2 years before enrollment with the exception of basal cell carcinoma.
  • Daily intake of long- and short-acting or controlled-release opioid analgesics of more than 200 mg morphine equivalents, regimens combining high-dose opioids and benzodiazepines, or any other treatment regimen considered unstable, unsafe, or have potential to affect the interpretation of the trial.
  • Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture, electromagnetic field treatment, or initiation/implementation of radiofrequency ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6 weeks prior to allocation to medicinal product.
  • Evidence of current alcohol or drug abuse, or history of alcohol or drug abuse within 2 years of enrollment, based on participant history and physical examination and according to the investigator's judgment.
  • Any other severe medical condition, including severe depression, or any other severe mood disorder, that in the opinion of the investigator may affect efficacy or safety assessments or may compromise the participant's safety during trial participation.
  • Participant is engaged in litigation related to their disability from CRPS in which monetary gain or loss (or other compensation) may affect their objective participation in the trial.
  • Women who are pregnant or breastfeeding.
  • Elevated (AST) or alanine aminotransferase (ALT) greater than 2-fold (ULN), or evidence or history of liver disease.
  • Participation in an investigational drug trial within 3 months prior to enrollment, or prior participation in this trial with receipt of any infusion of IMP, even a partial infusion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
459 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10

    Drug: Placebo

  • Experimental
    125 mg Neridronic acid

    Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10

    Drug: Placebo · Drug: Neridronic acid 62.5 mg

  • Experimental
    250 mg Neridronic acid

    Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10

    Drug: Neridronic acid 62.5 mg

Interventions

  • DrugPlacebo

    Matching placebo administered as intravenous infusion.

  • Neridronic acid administered as intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Change in the Pain Intensity Score to Week 12.

    The Pain Intensity Score is the mean value of current pain intensity ratings, obtained twice-daily for 1 week, using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine". All pain intensity ratings for the primary endpoint will be in reference to the CRPS-affected limb.

    Time frame: Baseline; Week 12

Secondary outcomes

  1. Response to treatment: Proportion of Participants With at Least 30 Percent Reduction in the Pain Intensity Score

    Participants with at least a 30 percent decrease in the Pain Intensity Score will be considered to have responded to treatment. The Pain Intensity Score is determined as for the primary endpoint.

    Time frame: Baseline; Week 12

  2. Response to treatment: Proportion of Participants With at Least 50 Percent Reduction in the Pain Intensity Score

    Participants with at least a 50 percent decrease in the Pain Intensity Score will be considered to have responded to treatment. The Pain Intensity Score is determined as for the primary endpoint.

    Time frame: Baseline; Week 12

  3. Change in the Brief Pain Inventory (BPI) Interference Score

    The BPI Interference Score is the mean value of 7 self-reported items in question 9 of the BPI Short Form Questionnaire. Participants will rate their interference of pain with general activity, walking, work, sleep and other activities in the past 24 hours, with possible ratings from 0 (does not interfere) to 10 (completely interferes). The BPI interference Score ranges from 0 to 10, with higher values indicating greater pain interference of daily activities.

    Time frame: Baseline; Week 12

  4. Patient Global Impression of Change (PGIC)

    The PGIC is a self-reported measure of perceived change in overall condition since the start of the study. Participants will select one of seven responses ranging from very much improved to very much worse. A response of very much improved or much improved is generally regarded as a clinically important outcome.

    Time frame: Baseline; Week 12

  5. Change in the EuroQol-5 Dimension 5 Level (EQ-5D-5L) Index Score

    The EQ-5D-5L Index Score describes the participant's overall health status and is derived from self-reported scores in 5 health dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Participants will rate each dimension at one of 5 levels, with level 1 indicating the best health state (no problems) and level 5 indicating worst health state (e.g., unable to walk about). The EQ-5D-5L Index Score ranges from 0 to 1, with 0 representing death and 1.0 representing perfect health.

    Time frame: Baseline; Week 12

  6. Change in the EuroQol Visual Analog Scale (EQ VAS)

    The EQ VAS is a self-reported measure of the participant's overall health "today". Participants will place a mark on a 20 cm vertical scale numbered from 0 to 100, with 0 labeled as "the worst health you can imagine" and 100 labeled as "the best health you can imagine". The EQ VAS ranges from 0 to 100, with higher scores representing better overall health.

    Time frame: Baseline; Week 12

Other outcomes

  1. Change in the Worst Pain Intensity

    This will be determined as for the primary endpoint, using worst pain intensity ratings. Participants will rate their worst pain intensity during the previous 12 hours twice each day using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine". Worst pain intensity ratings are in reference to the CRPS-affected limb.

    Time frame: Baseline; Week 12

  2. Change in the Average Pain Intensity

    This will be determined as for the primary endpoint, using average pain intensity ratings. Participants will rate their average pain intensity during the previous 12 hours twice each day using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine". Average pain intensity ratings are in reference to the CRPS-affected limb.

    Time frame: Baseline; Week 12

  3. Change from Baseline in the Pain Intensity Scores at Each Week

    Pain Intensity Scores will be determined as for the primary endpoint using current pain intensity ratings obtained twice-daily. Mean values will be assessed during each of the first 12 weeks of the study.

    Time frame: Baseline to Week 12

  4. Response to Treatment: Proportion of Participants with 0 to 100% Decrease in the Pain Intensity Score

    Pain Intensity Scores will be determined as for the primary endpoint using current pain intensity ratings obtained twice-daily. Participants will be considered to have responded to treatment using increments of 10% decrease in the Pain Intensity Score, starting from 0% (no decrease in the Pain Intensity Score), 10%, 20%, etc., to 100% (Pain Intensity Score at Week 12 = 0).

    Time frame: Baseline; Week 12

  5. Response to Treatment: Proportion of Participants With at Least a 2 Point Decrease in the Pain Intensity Score

    Pain Intensity Scores will be determined as for the primary endpoint using current pain intensity ratings obtained twice-daily. Participants will be considered to have responded to treatment if they have at least a 2 point decrease in the Pain Intensity Score.

    Time frame: Baseline; Week 12

  6. Change in the Pain Anxiety Symptom Scale (PASS) Total Score

    The PASS Total Score is the sum of 20 self-reported items in the PASS Questionnaire. Participants will rate each item in terms of its frequency, ranging from 0 (never) to 5 (always). The PASS Total Score ranges from 0 to 100, with higher scores indicating greater levels of pain-related anxiety.

    Time frame: Baseline; Week 12

  7. Change in the Center for Epidemiological Studies Depression (CES-D) Scale Total Score

    The CES-D Total Score is the sum of 20 self-reported items comprising symptoms associated with depression. Participants will rate each item in terms of its frequency from "rarely or none of the time (less than 1 day)" to "most or all of the time (5 to 7 days)" during the last week. The CES-D Total Score ranges from 0 to 60, with a score over 21 indicating the possibility of major depression.

    Time frame: Baseline; Week 12

  8. Change in Pain Disability Index (PDI)

    The PDI is the sum of self-reported ratings of disability in 7 categories of activities, including family/home responsibilities, recreation, social activity, self-care, etc. Participants will rate the level of disability that they typically experience due to pain in each of the 7 categories. Ratings are made using a numeric rating scale, with 0 indicating "no disability" and 10 indicating "worst disability". The PDI ranges from 0 to 70, with higher values indicating greater disability due to pain.

    Time frame: Baseline; Week 6; Week 12

  9. Change in the Medical Outcomes Study (MOS) Sleep Scale: Sleep Problems Index

    The MOS Sleep Scale Sleep Problems Index is derived from participant's responses to questions related to sleep adequacy, sleep disturbance, daytime somnolence, and other aspects of sleep. Participants will respond to 12 questions in the MOS Sleep Scale Questionnaire. Responses are scored, summed and converted to a 0 to 100 scale, with higher scores indicating worse sleep problems.

    Time frame: Baseline; Week 6; Week 12

  10. Change in Pain Medication Score

    The Pain Medication Score will be derived using the Medication Quantification Scale (MQS III) and is based entirely on information available from the participant's prior and concomitant medications. The MQS III algorithm derives a single numerical value representing the amount of pain medications taken by each participant, taking into account the medication class and dosage.

    Time frame: Baseline; Week 6; Week 12; Month 6; Month 9; Month 12

  11. Change in the Current Pain Intensity in the Extended Follow-up Period

    Participants will rate their current CRPS-related pain intensity at each visit in the extended follow-up period using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine".

    Time frame: Baseline; Month 6; Month 9; Month 12

  12. Change in the Average Pain Intensity in the Extended Follow-up Period

    Participants will rate their average CRPS-related pain intensity, recalled over the last 24 hours, at each visit in the extended follow-up period using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine".

    Time frame: Baseline; Month 6; Month 9; Month 12

  13. Change in the Worst Pain Intensity in the Extended Follow-up Period

    Participants will rate their worst CRPS-related pain intensity, recalled over the last 24 hours, at each visit in the extended follow-up period using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine".

    Time frame: Baseline; Month 6; Month 9; Month 12

  14. Change in the BPI Interference Score in the Extended Follow-up Period

    The BPI Interference Score is the mean value of 7 self-reported items in question 9 of the BPI Short Form Questionnaire. Participants will rate their interference of pain with general activity, walking, work, sleep and other activities in the past 24 hours, with possible ratings from 0 (does not interfere) to 10 (completely interferes). The BPI interference Score ranges from 0 to 10, with higher values indicating greater pain interference of daily activities.

    Time frame: Baseline; Month 6; Month 9; Month 12

  15. PGIC in the Extended Follow-up Period

    The PGIC is a self-reported measure of perceived change in overall condition since the start of the study. Participants will select one of seven responses ranging from very much improved to very much worse. A response of very much improved or much improved is generally regarded as a clinically important outcome.

    Time frame: Baseline; Month 6; Month 9; Month 12

  16. Change in the EQ-5D-5L Index Score in the Extended Follow-up Period

    The EQ-5D-5L Index Score describes the participant's overall health status and is derived from self-reported scores in 5 health dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Participants will rate each dimension at one of 5 levels, with level 1 indicating the best health state (no problems) and level 5 indicating worst health state (e.g., unable to walk about). The EQ-5D-5L Index Score ranges from 0 to 1, with 0 representing death and 1.0 representing perfect health.

    Time frame: Baseline; Month 6; Month 9; Month 12

  17. Change in the EQ VAS in the Extended Follow-up Period

    The EQ VAS is a self-reported measure of the participant's overall health "today". Participants will place a mark on a 20 cm vertical scale numbered from 0 to 100, with 0 labeled as "the worst health you can imagine" and 100 labeled as "the best health you can imagine". The EQ VAS ranges from 0 to 100, with higher scores representing better overall health.

    Time frame: Baseline; Month 6; Month 9; Month 12

  18. Change in the Complex Regional Pain Syndrome (CRPS) Severity Score

    The CRPS Severity Score is the sum of the number of CRPS-related symptoms, reported by the participant over the past 48 hours, and signs, observed by the clinician during a brief examination. Participants are queried for 8 CRPS-related symptoms and assessed for 8 CRPS-related signs, for a score between 0 and 16, with higher scores indicating greater CRPS severity.

    Time frame: Baseline; Week 6; Week 12; Month 6; Month 9; Month 12

  19. Presence or Absence of Complex Regional Pain Syndrome (CRPS)

    The presence or absence of CRPS will be determined based on CRPS-related signs, assessed by the clinician in a brief examination. Participant reported symptoms for CRPS from the Enrollment Visit will be included with signs applying the CRPS diagnostic criteria ("Budapest clinical criteria"). Participants who meet criteria for CRPS using the diagnostic criteria will be considered as "CRPS present", and those who do not meet the criteria will be considered as "CRPS absent".

    Time frame: Month 6; Month 9; Month 12

  20. Change from Baseline in Bone Turnover Markers

    Serum levels of bone formation markers (procollagen type I amino-terminal propeptide and bone alkaline phosphatase) and a bone resorption marker (C-terminal telopeptide of type I collagen) will be determined from blood samples taken during the trial. This information will be used for an exploratory evaluation of bone turnover in response to neridronic acid.

    Time frame: Baseline to Month 12

07

Study locations

59 sites
  • Site US119 - G & L Research
    Foley, Alabama 36535, United States
  • Site US117 - Valley Pain Consultants
    Scottsdale, Arizona 85254, United States
  • Site US116 - Arizona Pain Specialists
    Scottsdale, Arizona 85258, United States
  • Site US124 - Quality of Life Medical and Research Centers LLC
    Tucson, Arizona 85712, United States
  • Site US154 - Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Site US110 - Orange County Research Institute
    Anaheim, California 92801, United States
  • Site US172 - Core Healthcare Group
    Cerritos, California 90703, United States
  • Site US108 - Catalina Research Institute
    Chino, California 91710, United States
  • Site US175 - Inland Pain Medicine
    Colton, California 92324, United States
  • Site US152 - UC San Diego Healthcare Systems, Center for Pain Medicine
    La Jolla, California 92093, United States
  • Site US102 - Samaritan Center for Medical Research
    Los Gatos, California 95032, United States
  • Site US126 - Northern California Research
    Sacramento, California 95821, United States
  • Site US106 - Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Site US153 - Clinical Research of West Florida Inc - Clearwater
    Clearwater, Florida 33765, United States
  • Site US162 - South Lake Pain Institute
    Clermont, Florida 34711, United States
  • Site US143 - Florida Pain Institute
    Merritt Island, Florida 32953, United States
  • Site US122 - Precision Research Organization, LLC
    Miami Lakes, Florida 33016, United States
  • Site US111 - Sunrise Research Institute
    Miami, Florida 33130, United States
  • Site US104 - Discovery Clinical Trials
    Orlando, Florida 32806, United States
  • Site US133 - Gold Coast Research LLC
    Plantation, Florida 33317, United States
  • Site US171 - Florida Medical Pain Management
    Saint Petersburg, Florida 33709, United States
  • Site US121 - Clinical Research of West Florida
    Tampa, Florida 33603, United States
  • Site US165 - Palm Beach Research
    West Palm Beach, Florida 33409, United States
  • Site US131 - Better Health Clinical Research, Inc
    Newnan, Georgia 30265, United States
  • Site US103 - Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Site US129 - International Clinical Research Institute
    Overland Park, Kansas 66210, United States
  • Site US169 - Massachusetts General Hospital
    Boston, Massachusetts 01773, United States
  • Site US127 - Advance Clinical Research, Inc
    Saint Louis, Missouri 63128, United States
  • Site US105 - Advanced Biomedical Research of America
    Las Vegas, Nevada 89123, United States
  • Site US101 - Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Site US151 - Premier Pain Centers
    Shrewsbury, New Jersey 07702, United States
  • Site US156 - University Clinical Research Center
    Somerset, New Jersey 08502, United States
  • Site US166 - Albany Medical College
    Albany, New York 12208, United States
  • Site US137 - Montefiore Medical Center
    Bronx, New York 10467, United States
  • Site US145 - University of Rochester
    Rochester, New York 14618, United States
  • Site US135 - The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Site US157 - North Star Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Site US149 - Founders Research Corporation
    Philadelphia, Pennsylvania 19152, United States
  • Site US114 - Abington Neurological Associates
    Willow Grove, Pennsylvania 19090, United States
  • Site US112 - Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Site US107 - Austin Center for Clinical Research
    Austin, Texas 78756, United States
  • Site US134 - Lovelace Scientific Resources, Inc
    Austin, Texas 78758, United States
  • Site US113 - Pioneer Research Solutions, Inc
    Houston, Texas 77099, United States
  • Site US118 - Omega International Pain Clinic
    Salt Lake City, Utah 84106, United States
  • Site US164 - Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Site US144 - Bellevue Surgery Center
    Bellevue, Washington 98004, United States
  • Site US173 - Bellevue Surgery Center
    Bellevue, Washington 98004, United States
  • Site US123 - Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Site US161 - Swedish Pain and Headache Center
    Seattle, Washington 98104, United States
  • Site DE107 - Studienzentrum A. Schwittay
    Böhlen, 04564, Germany
  • Site DE104 - Schmerzzentrum Dr. med. C. Wachter & T. Tusker
    Fellbach, 70736, Germany
  • Site DE101 - Klinische Forschung Hannover Mitte GmbH
    Hannover, 30159, Germany
  • Site DE103 - Algesiologikum Studienzentrum und Algesiologikum MVZ
    Munich, 80799, Germany
  • Site DE102 - Universitätsklinikum Würzburg Neurologische Klinik
    Würzburg, 97080, Germany
  • Site GB104 - The Royal Victoria Infirmary
    Cambridge, NE1 4LP, United Kingdom
  • Site GB108 - Darlington Memorial Hospital, Centre for Research and clinical Intervention
    Darlington, DL3 6HX, United Kingdom
  • Site GB109 - Royal Devon Exeter Hospital
    Exeter, EX2 5DW, United Kingdom
  • Site GB101 - Guys and St. Thomas NHS Foundation Trust - St Thomas Hospital
    London, SE1 7EH, United Kingdom
  • Site GB111 - Chelsea and Westminster Hospital - NHS Foundation Trust
    London, SW10 9NH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Information available on the Grünenthal Group Web Site (see URL below for details); according to the EFPIA Data Sharing Principles.

Data sharing details ↗ · www.grunenthal.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Aug 2016, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2015
First posted
Mar 30, 2015
StartActual
Apr 2015
Primary completionActual
Aug 2016
CompletionActual
Nov 2016
Results delay requested
Feb 22, 2018
Last update
May 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02402530
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Mar 30, 2015
Start date
Apr 2015
Primary completion
Aug 2016
Completion
Nov 2016
Last update
May 9, 2018

Study contacts

Grünenthal Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neridronic acid

Start the discussion